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Abstract. 
 
Recently, a requirement for 
 
b
 
-arrestin–medi-
ated endocytosis in the activation of extracellular sig-
nal–regulated kinases 1 and 2 (ERK1/2) by several G 
protein–coupled receptors (GPCRs) has been pro-
posed. However, the importance of this requirement 
for function of ERK1/2 is unknown. We report that ag-
onists of G
 
a
 
q-coupled proteinase–activated receptor
2 (PAR2) stimulate formation of a multiprotein signal-
ing complex, as detected by gel ﬁltration, immunopre-
cipitation and immunoﬂuorescence. The complex, 
which contains internalized receptor, 
 
b
 
-arrestin, raf-1, 
and activated ERK, is required for ERK1/2 activation. 
However, ERK1/2 activity is retained in the cytosol and 
neither translocates to the nucleus nor causes prolifera-
tion. In contrast, a mutant PAR2 (PAR2
 
d
 
ST363/6A), 
which is unable to interact with 
 
b
 
-arrestin and, thus, 
does not desensitize or internalize, activates ERK1/2 by 
a distinct pathway, and fails to promote both complex 
formation and cytosolic retention of the activated 
ERK1/2. Whereas wild-type PAR2 activates ERK1/2 by 
a PKC-dependent and probably a ras-independent 
pathway, PAR2(
 
d
 
ST363/6A) appears to activate
ERK1/2 by a ras-dependent pathway, resulting in in-
creased cell proliferation. Thus, formation of a signaling 
complex comprising PAR2, 
 
b
 
-arrestin, raf-1, and acti-
vated ERK1/2 might ensure appropriate subcellular lo-
calization of PAR2-mediated ERK activity, and thereby 
determine the mitogenic potential of receptor agonists.
Key words: subcellular localization • MAP kinase • 
cytosol • receptor trafﬁcking
 
Introduction
 
Agonists of certain G protein–coupled receptors (GPCRs)
 
1
 
activate extracellular signal–regulated kinases 1 and 2
(ERK1/2), but do not induce their translocation into the
nucleus (Pouyssegur and Böhm, 1992; Alblas et al., 1996;
Post et al., 1996). Although the mitogenic effects of nuclear
ERK1/2 are the most often studied, a number of important
substrates of ERK1/2 are cytoplasmic. Some examples are
insulin receptor substrate-1, where phosphorylation by
ERK1/2 leads to cellular insulin resistance (DeFea and
Roth, 1997), cytoskeletal proteins, and microtubule-asso-
ciated proteins (MAPs; Sturgill and Ray, 1986; Ray and
Sturgill, 1988), where phosphorylation is involved in cell
migration, morphological alterations (Goedert et al., 1996;
Klemke et al., 1997), and phospholipase A
 
2
 
 (Bornfeldt et
al., 1997), which mediates many agonist-induced inflam-
matory responses. In addition, some of the transcription
factors that are activated by ERK1/2 are cytoplasmic, and
translocate to the nucleus after phosphorylation (Chen et al.,
1992). A number of stimuli converge on the same ERK cas-
cade to elicit specific biological responses. If a given agonist
is intended to induce ERK-dependent phosphorylation of
cytosolic substrates, but not induce proliferation, how does
the cell ensure that ERK activation results in the correct re-
sponse? An answer may lie in protein scaffolding complexes,
 
such as those observed for the 
 
b
 
2
 
-adrenergic receptor (
 
b
 
2
 
-
AR). In this instance, a signaling complex in clathrin-coated
endocytic vesicles comprising activated receptor, the clathrin
adaptor protein 
 
b
 
-arrestin, and Src, is required for ERK acti-
vation (Daaka et al., 1998; Luttrell et al., 1999). Similar re-
quirements have been found for other GPCRs (Ignatova et
al., 1999; Vögler et al., 1999). However, none of these stud-
ies have addressed the question of why the 
 
b
 
-arrestin–
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bound, internalized receptor would be required for activa-
tion of ERK1/2 when other signals transduced by the re-
ceptor occur while it is still at the cell surface.
The purpose of the present investigation was to define
the role of 
 
b
 
-arrestin–containing scaffolding complexes in
the activation and subcellular localization of ERK1/2. We
examined the role of these complexes in signal trans-
duction by proteinase-activated receptor-2 (PAR2), a
member of a new family of GPCRs for serine proteases
(Déry et al., 1998). Pancreatic trypsin and mast cell tryp-
tase cleave PAR2 within its extracellular NH
 
2
 
 terminus
(SKGR 
 
¯ 
 
SLIGRL/KV, 
 
¯
 
 cleavage site for rat/human
PAR2), exposing a tethered ligand domain (SLIGRL/KV)
that binds to and activates the cleaved receptor. PAR2 is
highly expressed in the gastrointestinal tract and pancreas.
Pancreatic trypsin activates PAR2 in enterocytes and in
epithelial cells of the pancreatic duct to regulate pros-
tanoid secretion and the activity of ion channels (Kong
et al., 1997; Nguyen et al., 1999). Tryptase, a major pro-
tease of human mast cells, activates PAR2 in enteric myo-
cytes and neurons, and PAR2 may mediate some of the
mitogenic and proinflammatory effects of tryptase (Cor-
vera et al., 1997, 1999). In view of the potential importance
of PAR2 in normal regulation, inflammation and mitogen-
esis (Déry et al., 1998), it is important to understand the
mechanisms of PAR2 signal transduction. PAR2 couples
G
 
a
 
q/11 and phospholipase C
 
b
 
, leading to hydrolysis of
phosphatidylinositol bisphosphate, Ca
 
2
 
1
 
 mobilization, and
activation of protein kinase C (PKC) and ERK1/2 (Déry
et al., 1998). Agonist-induced desensitization of PAR2 in-
volves receptor phosphorylation and endocytosis by a
 
b
 
-arrestin and clathrin-dependent mechanism (Böhm et
al., 1996; Déry et al., 1999).
We investigated the role of 
 
b
 
-arrestins as molecular
scaffolds that organize and recruit components of the
mitogen-activated protein (MAP) kinase cascade, and
thereby ensure the proper localization and specificity of
activated ERK1/2. Our aims were as follows: to determine
if 
 
b
 
-arrestin–dependent receptor endocytosis is required
for PAR2-mediated ERK activation; identify components
of this pathway that interact with 
 
b
 
-arrestins; investigate
whether a desensitization and internalization-resistant
PAR2 mutant, which does not interact with 
 
b
 
-arrestins,
activates ERK1/2 by alternative pathways; and examine
whether the formation of the complex affects the localiza-
tion and specificity of ERK1/2.
 
Materials and Methods
 
Materials
 
Unless otherwise specified, all reagents were from Sigma Chemical Co.
Trypsin (TPCK-treated) was from Worthington Biochemical, Inc. Pep-
tides corresponding to the tethered ligand domains of rat and human
PAR2 (activating peptides, AP: rat SLIGRL-NH
 
2
 
; human SLIGKV-NH
 
2
 
)
were synthesized on solid phase and purified by high pressure liquid chro-
matography. SLIGKV-NH
 
2
 
 was used as an agonist of transfected cells ex-
pressing human PAR2, and SLIGRL-NH
 
2
 
 was used to stimulate rat en-
terocytes. Fura-2/AM and propidium iodide were from Molecular Probes,
Inc. An expression vector for enhanced green fluorescent protein
(pEGFP-N1) was from CLONTECH Laboratories. A Geneditor kit was
from Promega Corp. Expand polymerase was from Boehringer Mann-
heim. Phosphocellulose columns and enhanced chemiluminescence detec-
tion kits were from Pierce Chemical Co. PVDF membranes were from
New England Nuclear. 4
 
a
 
-phorbol 12,13-dicanoate (PDB) was from Cal-
biochem-Novabiochem Corp. Protein A–agarose and Lipofectin were
from GIBCO BRL. 
 
b
 
-Arrestin-1 cDNA was a gift from Dr. R.J. Lefko-
witz (Duke University, Durham, NC). pCEP-ERK2 was from Dr. M.
Cobb (University of Texas, Dallas, TX). N17ras was from Dr. A. Weiss
(University of California, San Francisco, San Francisco, CA). Kirsten mu-
rine sarcoma virus–transformed rat kidney epithelial cells (KNRK) were
from the American Type Tissue Culture Collection (ATCC CRL 1569). A
 
rat enterocyte cell line hBRIE380, which highly expresses PAR2 (26),
was from Dr. G. Aponte (University of California, Berkeley, Berkeley,
CA). HEK293 cells were from Dr. R. Roth (Stanford University, Stan-
ford, CA).
 
Antibodies
 
The following antibodies were used: phosphorylated ERK1/2 (pERK1/2),
total ERK1/2 conjugated to agarose beads, c-src, Shc, phosphotyrosine
(PY-99), and G-actin (Santa Cruz Biotechnology); total ERK1/2 (Zymed
Labs, Inc.); 
 
b
 
-arrestin-1, raf-1, PYK2, and histone (Transduction Labs);
 
b
 
-arrestin-1/2 (a gift from Dr. R.J. Lefkowitz); enhanced green fluores-
cent protein (EGFP; McConalogue et al., 1998) (a gift from Dr. J.H.
Walsh, University of California, Los Angeles, CA); Flag M1 (Interna-
tional Biotechnologies Inc.); HA.11 to the hemagglutinin 12CA5 epitope
(YPYDVPDYA) Berkeley Antibody Co.; HA.11 conjugated to HRP,
Boehringer. Secondary antibodies coupled to FITC and Texas red were
from Jackson ImmunoResearch Laboratories, Inc. A secondary antibody
conjugated to (R)-phycoerythrin was from Caltag Laboratories. A sec-
ondary antibody conjugated to HRP was from Pierce Chemical Co.
A rabbit polyclonal antibody (PAR2N) raised to an NH
 
2
 
-terminal frag-
ment of human PAR2 (
 
¯
 
37
 
SLIGKVDGTSHVTGKG
 
53
 
V, 
 
¯
 
 trypsin cleav-
age site) was from Dr. P. Andrade-Gordon (Johnson and Johnson, PRI).
 
This antibody detected a single protein of 80 kD on Western blots of
hBRIE cells, and proteins of 49 and 78 kD on blots of KNRK cells ex-
 
pressing human PAR2 with a 12CA5 epitope (Böhm et al., 1996). These
proteins were not detected in untransfected KNRK cells, which express
PAR2 only at very low levels. The signals were abolished by preincubation
of the antibody with the receptor fragment used for immunization. The 78-
kD protein represents glycosylated PAR2 as it can be reduced to 49 kD
(corresponding to the mass of PAR2) by with endoglycosidase. Further,
both proteins cross-reacted with an antibody to the 12CA5 epitope. A rab-
bit polyclonal antiserum (B5) raised to a peptide corresponding to rat
 
PAR2 (
 
30
 
GPNSKGR
 
¯
 
SLIGRLDT
 
46
 
P-YGGC) was from Dr. M. Hollen-
berg (University of Calgary, Alberta, Canada; Kong et al., 1997).
 
Plasmid Construction and Generation of Cell Lines
 
KNRK cells were stably transfected with human PAR2 alone, or with
PAR2 plus rat 
 
b
 
-arrestin-1 tagged with COOH-terminal green fluorescent
protein (GFP, designated ARR-GFP), or a fragment of 
 
b
 
-arrestin
 
319-418
 
tagged with GFP (ARR
 
319-418
 
-GFP), as described (Déry et al., 1999). This
 
fragment corresponds to the clathrin-binding domain of 
 
b
 
-arrestins, and
is a dominant negative mutant for 
 
b
 
-arrestin–mediated endocytosis. The
human PAR2 construct comprised NH
 
2
 
-terminal Flag proximal to the
trypsin cleavage site and COOH-terminal 12CA5 epitopes (Böhm et al.,
1996). For some experiments hBRIE cells were stably transfected with
ARR-GFP or with ARR
 
319-418
 
-GFP using Lipofectin (Déry et al., 1999).
The point mutant PAR2(
 
d
 
ST363/6A) was created using the Geneditor
kit according to manufacturer’s instructions. The mutagenic oligonucle-
otide (OPERON Technologies) contained a Dde1 site, which allowed
identification of mutant PAR2 by restriction digestion. DNA was se-
quenced to confirm the mutation. KNRK cells were stably transfected
with PAR2(
 
d
 
ST363/6A) alone or cotransfected with either ARR-GFP or
ARR
 
319-418
 
-GFP using Lipofectin, and were selected and maintained as
described for KNRK-PAR2 cells (Déry et al., 1999). HEK293 cells
were transfected with human PAR2 alone, PAR2 plus ARR-GFP or
ARR
 
319-418
 
-GFP, or with PAR2
 
d
 
ST363/6A using Lipofectin. Stable cell
lines were selected and maintained as described (Déry et al., 1999). Rat-
ERK2 was amplified from pCEP-ERK2 by PCR and ligated into pEGFP-
N1 at Bgl2 and Age1 sites, to generate ERK2-GFP. DNA was sequenced
to confirm that the fusion junction was in-frame. To visualize transloca-
tion of ERKs, KNRK-PAR2 and KNRK-PAR2(
 
d
 
ST363/6A) cells were
transiently transfected with ERK2-EGFP using calcium phosphate, as de-
scribed (DeFea and Roth, 1997). To examine the role of ras in ERK acti-
vation, KNRK-PAR2 and KNRK-PAR2(
 
d
 
ST363/6A) cells were stably
transfected with dominant negative pcDNA3.1-N17ras using Lipofectin. 
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Two to three individual clones of each cell line were screened for ex-
pression of PAR2 or 
 
b
 
-arrestins by measuring Ca
 
2
 
1
 
 mobilization in re-
sponse to PAR2 agonists, by flow cytometry and Western blotting. Se-
lected clones expressed PAR2 or 
 
b
 
-arrestins at similar levels and, thus,
single clones were used in the remainder of the studies. Untransfected
KNRK cells did not express significant levels of PAR2, as demonstrated
by lack of Ca
 
2
 
1
 
 mobilization in response to PAR2 agonists and lack of
immunoreactivity to PAR2 on Western blots. Levels of endogenous
 
b
 
-arrestins were slightly higher in KNRK and 293 cells than in hBRIE
cells as detected by Western blotting.
 
MAPK Assays
 
Confluent cells were maintained in minimal essential medium without se-
rum overnight and incubated with 50 nM trypsin or 50 
 
m
 
M AP for 0–60
min at 37
 
8
 
C. Cells were incubated with 100 nM GF109203X, 20 nM
LY379196, 10 
 
m
 
M genistein, and 20 
 
m
 
M tyrphostin-25 for 20 min or with
100 ng/ml pertussis toxin (PTX) for 24 h. Vehicle was used for controls.
Cells were lysed in RIPA (PBS with 1% NP-40, 0.25% sodium deoxycho-
late, 400 nM okadaic acid, and 2 mM orthovanadate and protease inhibi-
tors), and ERK1/2
 
 
 
were immunoprecipitated by incubating 300 
 
m
 
g total
protein with ERK
 
 
 
antibodies coupled to agarose beads. For measurement
of ERK1/2 activity, beads were washed and incubated with 5 mM myelin
basic protein (MBP) in the presence of 1 
 
m
 
Ci 
 
g
 
[
 
32
 
P]ATP and 10 
 
m
 
M cold
ATP in 50 mM Tris-HCl, pH 7.6, 6 mM MgCl
 
2
 
, and 2 mM MnCl
 
2
 
 for 30
min at room temperature. Reactions were stopped by centrifugation and
an addition of an equal volume of Laemmli sample buffer to the superna-
tant or by binding MBP to a phosphocellulose column. Samples were ana-
lyzed by 20% SDS-PAGE and autoradiography. Phosphorylation was as-
sessed by counting excised MBP bands or phosphocellulose-bound MBP.
All counts were normalized to the MBP band density and immunoprecipi-
tated ERK1/2. MBP was identified by Coomassie staining of gels. To de-
tect total immunoprecipitation of ERK1/2, the immunoprecipitates were
boiled, analyzed by 12% SDS-PAGE, transferred to PVDF membranes,
and incubated with antibody to total ERK1/2 (1:1,000, overnight, 4
 
8
 
C),
followed by goat anti–rabbit IgG conjugated to HRP (1:20,000 for 1 h at
room temperature). Proteins were visualized by enhanced chemilumines-
cence. Autoradiograms and Coomassie-stained gels were photographed
using a digital camera, and images were analyzed using Adobe Photoshop
4.0. Band density was determined by histogram analysis (mean density 
 
3
 
number pixels). The total counts per minute present in each excised band
was normalized to both the density of the MBP band and the ERK1/2
bands representing the amount of ERK present in each reaction. Activa-
tion of ERK1/2 was also assessed by Western blotting using antibodies to
phospho-ERKs. 10 
 
m
 
g of total protein was removed before immunopre-
cipitation, analyzed by 12% SDS-PAGE, and transferred to PVDF mem-
branes. Membranes were incubated with pERK antibody (1:400, overnight,
4
 
8
 
C), followed by goat anti–mouse IgG conjugated to HRP (1:30,000, for
1 h at room temperature). Blots were stripped in 2% SDS/1 mM 
 
b
 
-mer-
captoethanol in 50 mM Tris-HCl, pH 6.8, 150 mM NaCl for 60 min,
washed, and reprobed with antibody to total ERK1/2 to ensure equal lev-
els of ERK1 and 2 were present at each time point. Results were normal-
ized as described for the total amount of ERK 1 and 2 in each reaction.
Phosphorylation was assessed by histogram analysis of both ERK1 and
ERK2 band densities (mean density 
 
3
 
 number pixels) and fold phosphor-
ylation over basal was calculated. Fold phosphorylation of ERK1 and
ERK2 was not substantially different; thus, ERK1 and 2 band densities
were added together and were represented as ERK1/2 phosphorylation.
 
Subcellular Fractionation
 
For subcellular localization of pERK, cells were treated as described, rup-
tured in hypotonic buffer (HPB: 50 mM Hepes, pH 7.6, 1 mM MgCl
 
2
 
, 2 mM
orthovanadate, 500 nM okadaic acid, and protease inhibitors) with 25
strokes in a glass Dounce homogenizer, and centrifuged at 800
 
 g 
 
for 10
min. Supernatants were cleared at 100,000
 
 g
 
,
 
 
 
and the cytosolic protein was
precipitated with 10 vol of ice-cold acetone. Cytosolic protein pellets and
plasma membrane pellets were resuspended in HPB
 
 1
 
 0.1% NP-40. Nu-
clei-containing pellets from the low-speed spin were washed in HPB, re-
suspended in HPB 
 
1 
 
0.1% NP-40 and pelleted at 10,000 
 
g
 
. Nuclear super-
natants were precipitated with 10% ice-cold acetone and saved for
analysis. Nuclei were resuspended in Laemmli buffer and sonicated for 30 s.
pERK was determined in cytosolic and nuclear pellets by Western blot-
ting. The identity of nuclear and cytosolic fractions was confirmed by
Western blotting with antibodies to histone and G-actin, respectively.
 
Immunoprecipitation
 
Cells were maintained overnight in minimal essential medium without se-
rum overnight, incubated with 50 nM trypsin or 50 
 
m
 
M AP for 0–30 min at
37
 
8
 
C, and lysed in RIPA. For KNRK-PAR2, KNRK-PAR2(
 
d
 
ST363/6A),
and KNRK-PAR2
 
1
 
ARR
 
319-418
 
-GFP cells, 500 
 
m
 
g total protein was incu-
bated with either 1 
 
m
 
g of antibody to 
 
b
 
-arrestin-1/2, 500 ng antibody to
c-src, 1 
 
m
 
g antibody to PYK2, or 500 ng antibody to Shc. For hBRIE-ARR-
GFP, KNRK-PAR2
 
1
 
ARR-GFP, KNRK-PAR2
 
1
 
ARR
 
319-418
 
-GFP, and
KNRK-PAR2(
 
d
 
ST363/6A)
 
1
 
ARR-GFP cells, 500 
 
m
 
g total protein was
immunoprecipitated with 2 
 
m
 
g of antibody to GFP. Polyclonal antibodies
were prebound to 40 
 
m
 
l of protein A–agarose for 2 h at 4
 
8
 
C. mAbs were
incubated with equal concentrations of rabbit anti–mouse IgG before
binding protein A. Beads were washed twice in TBS (50 mM Tris-HCl, pH
8.0, and 150 mM NaCl), and boiled in Laemmli sample buffer. Proteins
were analyzed by 10% SDS-PAGE, followed by Western blotting with an-
tibodies to raf-1 (1:300) or phosphotyrosine (1:500). Blots were stripped
and reprobed with monoclonal 
 
b
 
-arrestin-1 antibody (1:1,000) to ensure
equal levels of 
 
b
 
-arrestin-1 in all lanes or with PYK2 (1:1,000) or Shc (1:
500) antibodies to confirm equal levels and identity of phosphoproteins.
 
Gel Filtration
 
Cells were lysed in RIPA as described. Lysates were loaded onto a col-
umn (3 
 
3 
 
150 cm, 400 ml bed volume) of S300 Sephacryl preequilibrated
in PBS. Proteins were eluted in PBS at 1.1 ml/min, and fractions were col-
lected at 7-min intervals. The column was calibrated with Dextran blue, 3 M
KCl, 8.5 nm thyroglobulin, 5.2 nm catalase, 3.5 nm BSA, and 1.8 nm myo-
globin. Absorbance of each fraction was measured at 290 nm. Proteins in
the fractions from the included volume were precipitated with methanol/
chloroform and analyzed by 10% SDS-PAGE, followed by Western blot-
ting with antibodies to PAR2 (HA.11 or 2N), 
 
b
 
-arrestin-1, raf-1, pERK,
and total ERK1/2, as described. The band densities for each protein were
divided by the sum of the band densities of all fractions (100%) in the in-
cluded volume to determine the percentage of the total protein eluting in
each fraction. Partition coefficients (
 
s
 
), error function complements of 
 
s
 
,
and Stoke’s radii were calculated according to the method of Ackers
(Chun et al., 1969). Fractions that were found to contain all four proteins
were pooled and concentrated 30-fold by dialysis against solid sucrose at
4
 
8
 
C, followed by dialysis against PBS overnight at 4
 
8
 
C. Concentrated pro-
teins were immunoprecipitated with antibodies to 
 
b
 
-arrestin-1/2 (1 
 
m
 
g/ml,
bound to protein A-agarose) or pERK1/2 (1 
 
m
 
g/ml bound to protein
A–agarose).
 
Immunofluorescence and Confocal Microscopy
 
Cells grown on glass coverslips were maintained in minimal essential me-
dium without serum overnight and incubated with 50 nM trypsin for 0–30
min at 378C. Cells were fixed in 4% paraformaldehyde in 100 mM PBS,
pH 7.4, for 20 min at 48C, washed in PBS, and incubated in PBS containing
0.5% Tween and 1% BSA for 30 min. PAR2 was localized using a mouse
monoclonal HA.11 antibody (1:5,000, overnight, 48C; Déry et al., 1999).
b-Arrestin-1 was detected using GFP (in KNRK-PAR21ARR-GFP
cells) or by immunofluorescence using an antibody to b-arrestin-112
(1:1,000, overnight, 48C, KNRK-PAR2(dST363/6A) cells) (Déry et al.,
1999). Raf-1 was localized by immunofluorescence using a mouse mAb
(1:500, overnight, 48C). Secondary antibodies coupled to FITC (for
b-arrestin-112) or Texas red (for HA.11 and raf-1) were used (1:200, for
2 h at room temperature). Cells were observed using a Bio-Rad MRC
1000 laser scanning confocal microscope, a Zeiss Axiovert 1003 micro-
scope, and a Zeiss 1003 Plan-Apochromat oil immersion objective (NA
1.4; Déry et al., 1999). For observations of trafficking in real time, KNRK-
PAR2 and KNRK-PAR2(dST363/6A) cells transiently expressing ERK2-
GFP were maintained at 378C in a microincubator. Care was taken to min-
imize laser exposure by limiting the number of optical sections (2–3 per
time point) and the laser intensity (,3%, NA 3–4 mm), to maintain cell
viability (Déry et al., 1999). Parallel time points were fixed, stained with
DAPI, and observed using a Zeiss Axioplan fluorescence microscope with
a Zeiss 1003 Plan-Apochromat oil immersion objective to confirm nu-
clear localization.
Flow Cytometry
Flow cytometry was used to quantify removal of PAR2 from the plasma
membrane and to thereby determine the rate of endocytosis. Cells were
incubated with 50 mM AP for 0–30 min at 378C, and surface Flag immu-The Journal of Cell Biology, Volume 148, 2000 1270
noreactivity was quantified by flow cytometry (Déry et al., 1999). Like
trypsin, AP induces PAR2 endocytosis (Böhm et al., 1996) but without re-
moving the Flag epitope. Transfected cells were incubated with 10 mg/ml
M1 antibody for 1 h at 48C, washed, and incubated with 2 mg/ml phyco-
erythrin-conjugated goat anti–mouse IgG for 1 h at 48C. hBRIE cells were
incubated with 2 mg/ml B5 antibody for 1 h at 48C, washed, and incubated
with 2 mg/ml FITC-conjugated goat anti–rabbit IgG for 1 h at 48C. Surface
fluorescence was analyzed with a Facscan flow cytometer (Becton Dickin-
son Co.). Fluorophores were excited at 488 nm and emission was collected
at 575 nm for phycoerythrin and 530 nm for FITC. Viability was assessed
by exclusion of propidium iodide.
Measurement of [Ca21]i
Cells were incubated in physiological salt solution (PSS [in mM]: 137
NaCl, 4.7 KCl, 0.56 MgCl2, 2 CaCl2, 1.0 Na2HPO4, 10 N-2-hydroxyethyl
piperazine-N9-2-ethanesulphonic acid, 2.0 L-glutamine, and 5.5 D-glucose,
pH 7.4) containing 0.1% BSA and 5 mM Fura-2/AM for 20 min at 378C.
They were washed and mounted in a microincubator containing 1 ml of
PSS-BSA at 378C on the stage of a Zeiss Axiovert 100 TV microscope.
Agonists were directly added to the bath. Cells were observed with a Zeiss
Fluar 403 objective (NA 1.30) and fluorescence was detected in individ-
ual cells using an ICCD video camera (Stanford Photonics) and a video
microscopy acquisition program (Axon Instruments; Corvera et al., 1997,
1999). Fluorescence was measured at 340 and 380 nm excitation and 510
nm emission. The ratio of the fluorescence at the two excitation wave-
lengths, which is proportional to the [Ca21]i, was determined. For concen-
tration-response experiments, cells were exposed to a single concentration
of agonist. To examine homologous desensitization, cells were repeatedly
challenged with agonists without an intervening wash (Böhm et al., 1996).
To examine the role of PKC in desensitization, cells were incubated with
1 mM PDB for 20 min before agonist challenge (Böhm et al., 1996).
Proliferation Assays
KNRK-PAR2, KNRK-PAR2(dST363/6A), and hBRIE cells were seeded
at 104 cells/well in 24-well plates, grown to 80% confluence, and main-
tained in minimal essential medium without serum overnight. Cells were
incubated with 50 mM AP or 20% FCS for 24 h at 378C. During the last 20 h,
1 mCi [3H]thymidine was added. Cells were washed, DNA was obtained
by solubilization in 0.2 M NaOH, and incorporated [3H]thymidine was
measured by scintillation counting. Cells were also counted in a hemacy-
tometer. Results are expressed as the fold increase over untreated cells.
Statistical Analyses
Results are expressed as mean 6 standard error. Differences between
multiple groups were examined by ANOVA and Student-Newman-Keuls
test, with P , 0.05 considered to be significant.
Results
Expression of Dominant Negative b-Arrestin Inhibits 
PAR2-mediated ERK Activity
We have previously shown that expression of b-arrestin319-418
prevents agonist-induced endocytosis of PAR2, and that
overexpression of ARR-GFP has no effect on endocytosis
or on the magnitude and duration of Ca21 signaling (Déry
et al., 1999). To examine the importance of b-arrestin–medi-
ated receptor endocytosis for activation of ERK1/2, we
coexpressed human PAR2 (NH2-terminal Flag, COOH-
terminal HA.11 epitopes) with either b-arrestin-1 fused to
green fluorescent protein (ARR-GFP) or with a dominant
negative fragment of b-arrestin fused to GFP (ARR319-418-
GFP) in KNRK cells (Déry et al., 1999). We assayed
ERK activity using MBP as a substrate. In KNRK-
PAR21ARR-GFP cells, 50 nM trypsin stimulated a peak
ERK activity of 5.76 6 0.8-fold over basal at 5 min (Fig. 1
a, d). In contrast, in KNRK-PAR21ARR319-418-GFP cells,
ERK1/2 activation was significantly diminished to only 1.8 6
0.3-fold over basal at 5 min, and trypsin only induced a sig-
nificant elevation of 2.3 6 0.3-fold after 30 min (P , 0.05;
Fig. 1 a, s). To ensure that trypsin-stimulated MBP activ-
ity was not an artifact of PAR2 overexpression in trans-
fected cells, we repeated the experiment in hBRIE cells,
an enterocyte cell line naturally expressing PAR2 (Kong
et al., 1997). In hBRIE cells, 50 nM trypsin stimulated
peak of 4.4 6 1-fold over basal at 5 min (Fig. 1 a, u).
Similar results were obtained using pERK antibodies to
detect activated, phosphorylated ERK1/2. Thus, 50 nM
trypsin maximally stimulated a 5.0 6 0.3-fold increase in
ERK1/2 phosphorylation in KNRK-PAR21ARR-GFP
cells (Fig. 1 b, d), but only a 1.2 6 0.4-fold increase in
KNRK-PAR21ARR319-418-GFP cells (Fig. 1 b, e). Simi-
larly, 50 nM trypsin maximally stimulated a 5.1 6 0.4-fold
increase in ERK1/2 phosphorylation in KNRK-PAR2 cells
(Fig. 1 b, e). Comparable results were obtained in entero-
cytes, where 50 nM trypsin stimulated maximal ERK1/2
phosphorylation by 5.0 6 0.3-fold in hBRIE cells (Fig. 1 c,
h), 4.85 6 0.45-fold in hBRIE1ARR-GFP cells (Fig. 1 c,
j), but by only 1.5 6 0.2-fold in hBRIE1ARR319-419-GFP
cells (Fig. 1 c, r).
Figure 1. PAR2-mediated activation of ERK1/2. (a) KNRK-
PAR21ARR-GFP cells (d) and KNRK-PAR21ARR319-418-
GFP cells (s) and hBRIE cells (h) were incubated with 50 nM
trypsin for 0–60 min at 378C, and ERK activity was measured us-
ing the MBP assay. (b–d) Western blots using antibodies to
pERK1/2. (b) KNRK-PAR21ARR-GFP cells (d), KNRK-
PAR2 cells (e), and KNRK-PAR21ARR319-418-GFP cells (s)
were incubated with 50 nM trypsin. (c) hBRIE cells (h),
hBRIE1ARR-GFP (e), and hBRIE1ARR319-418-GFP (r) were
incubated with 50 nM trypsin for 0–30 min at 378C. (d) KNRK-
PAR21ARR-GFP cells (d) and KNRK-PAR21ARR319-418-
GFP cells (s) were incubated 50 mM AP for 0–30 min at 378C. *P ,
0.05 compared with cells expressing PAR2 alone or PAR2 plus
ARR-GFP cells, n 5 4.DeFea et al. b-Arrestin and ERK Localization 1271
To ensure that the effect of trypsin on ERK1/2 activa-
tion was due to PAR2 stimulation and not to other effects
of trypsin on the cell, we examined the ability of the AP
corresponding to the PAR2-tethered ligand to stimulate
ERK1/2. In KNRK-PAR21ARR-GFP cells, 50 mM AP
stimulated a 4.8 6 0.5-fold increase in ERK phosphoryla-
tion that was not observed in KNRK-PAR21ARR319-418-
GFP cells (Fig. 1 d). Similar results were observed with
hBRIE cells (not shown).
These results were confirmed in a human embryonic
kidney fibroblast cell line, HEK293 cells, where trypsin
stimulated a 5.0 6 0.2 and a 5.3 6 0.6-fold increase in
ERK1/2 phosphorylation in cells expressing PAR2 alone
or PAR21ARR-GFP, respectively. Coexpression of
ARR319-418-GFP with PAR2 inhibited trypsin-stimulated
ERK1/2 activation in HEK 293 cells by 90 6 10% (not
shown). Phorbol ester–stimulated ERK1/2 phosphoryla-
tion was unaffected by expression of b-arrestin319-418, indi-
cating that there is not a basic requirement for b-arrestin
in all mechanisms of MAPK activation (not shown).
Together, these results indicate that PAR2 agonists acti-
vate ERK1/2 in transfected cell lines (KNRK and HEK)
and in enterocytes (hBRIE) that naturally express this re-
ceptor. Expression of b-arrestin319-418, which we have pre-
viously shown to suppress agonist-induced endocytosis of
PAR2 (Déry et al., 1999), inhibits PAR2-mediated ERK1/2
activation in both transfected cells and in hBRIE cells.
However, overexpression of b-arrestin does not affect this
response (Fig. 1, b–d).
An Internalization-resistant and
Desensitization-defective PAR2 Mutant
Activates ERK1/2
We have previously reported that PAR2-induced Ca21
mobilization is rapidly attenuated and desensitized (Böhm
et al., 1996). The mechanism of desensitization probably
involves phosphorylation of the PAR2 intracellular C-tail
by G protein receptor kinases and PKC, and association
with b-arrestins, which uncouple the receptor from het-
erotrimeric G proteins and also serve as clathrin adaptors
for endocytosis (Böhm et al., 1996; Déry et al., 1999). b-Arres-
tin319-418 corresponds to the clathrin binding domain of
b-arrestins. Expression of this mutant prevents PAR2 in-
ternalization but does not affect desensitization, so that
KNRK-PAR21ARR319-418-GFP cells signal normally, and
this signal is rapidly desensitized. Moreover, overexpres-
sion of ARR-GFP does not affect PAR2 internalization,
desensitization, or Ca21 mobilization (Déry et al., 1999).
To examine the requirement of receptor endocytosis
and desensitization for activation of ERK1/2, we mutated
several potential phosphorylation sites in the cytoplasmic
tail of PAR2. A double point mutant, in which serine
and threonine at codons 363 and 366 were changed to ala-
nines PAR2(dST363/6A), showed markedly reduced recep-
tor desensitization and internalization. Trypsin stimulated
Ca21 mobilization in both KNRK-PAR2 and KNRK-
PAR2(dST363/6A) cells with a similar efficacy, although
with a higher potency in KNRK-PAR2(dST363/6A) cells
(Fig. 2 a). The duration of activation was measured as
the time during which Ca21 mobilization was .200% of
the baseline. In KNRK-PAR2(dST363/6A) cells, 10 nM
trypsin induced a Ca21 response that remained elevated
for 3 6 0.05 times longer than in KNRK-PAR2 cells (Fig.
2 b). Homologous desensitization was assessed by re-
peated challenge of cells with AP and trypsin. Incubation
of KNRK-PAR2 cells with 10 mM AP for 5 min desensi-
tized the response to 10 nM trypsin, which was applied 5
min later, by 80 6 10% compared with the vehicle-treated
control cells (Fig. 2 c). In contrast, this treatment did
not induce discernible desensitization in KNRK-PAR2
(dST363/6A) cells. Heterologous desensitization was as-
sessed by pretreatment of cells with PDB to activate PKC.
Preincubation of KNRK-PAR2 cells with 1 mM PDB for
20 min abolished responses to 10 nM trypsin (Fig. 2 d).
However, this treatment had no effect on trypsin-induced
Ca21 mobilization in KNRK-PAR2(dST363/6A) cells.
These data suggest that the mutant PAR2(dST363/6A) re-
Figure 2. PAR2-mediated Ca21 mobilization in KNRK-PAR2
cells and KNRK-PAR2d(ST363/6A) cells. (a) Concentration-
response analysis for KNRK-PAR2 (d) and KNRK-PAR2
(dST363/6A) (m) cells. (b–d) Each line shows [Ca21]i for individ-
ual KNRK-PAR2 cells (left) and KNRK-PAR2(dST363/6A)
cells (right). (b) Note that the response to trypsin is prolonged in
KNRK-PAR2(dST363/6A) cells. (c) Homologous desensitization
in cells pretreated with 10 mM AP for 5 min before addition of 10
nM trypsin. (d) Heterologous desensitization in cells pretreated
with 1 mM PDB for 20 min before addition of 10 nM trypsin.
Note that KNRK-PAR2(dST363/6A) cells are resistant to desen-
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ceptor is resistant to homologous and heterologous desen-
sitization.
To assess PAR2 endocytosis, we incubated cells with
50 mM AP and quantified the surface Flag immunoreactiv-
ity by flow cytometry (Déry et al., 1999). In KNRK-PAR2
or KNRK-PAR21ARR-GFP cells, AP stimulated rapid
internalization of PAR2 (33 6 12% and 31 6 10% inter-
nalization at 5 min; 73 6 13% and 71 6 15% at 30 min,
respectively; Fig. 3 a, d). In marked contrast, in KNRK-
PAR2(dST363/6A) cells, there was no significant internal-
ization even after 30 min (Fig. 3 a, m). Similarly, AP-
induced endocytosis of PAR2 was markedly diminished in
KNRK-PAR21ARR319-418 cells (Fig. 3 a, s). In hBRIE
cells, AP also stimulated rapid internalization of PAR2 (70 6
5% at 5 min; 90 6 10% at 30 min; Fig. 3 a, h). Thus, the
PAR2 expressed in KNRK cells and enterocytes under-
goes agonist-induced endocytosis. Endocytosis is inhibited
by the expression of dominant negative b-arrestin319-418,
but is not affected by overexpression of wild-type b-arres-
tin. PAR2(dST363/6A) is highly resistant to agonist-induced
endocytosis.
To determine the effects of agonists on the subcellular
distribution of PAR2 and b-arrestin, we incubated cells
with 50 nM trypsin and localized PAR2 and b-arrestins
by confocal microscopy. Agonist-induced trafficking of
PAR2 is similar in KNRK-PAR2 cells and KNRK-
PAR21ARR-GFP cells (Böhm et al., 1996; Déry et al.,
1999). In KNRK-PAR21ARR-GFP cells, trypsin stimu-
lated rapid redistribution of b-arrestin from the cytosol to the
plasma membrane, where it colocalized with PAR2 at 5
min, followed by endocytosis of PAR2 and b-arrestins into
the same endosomes at 30 min (Fig. 3 b; Déry et al., 1999).
In KNRK-PAR2(dST363/6A) and KNRK-PAR2(dST363/
6A)1ARR-GFP cells in the absence of agonist, PAR2 was
Figure 3. Agonist-induced
PAR2 internalization. (a)
Kinetics of PAR2 endocyto-
sis in KNRK-PAR21ARR-
GFP cells (d), KNRK-PAR2
cells (e) KNRK-PAR21
ARR319-418-GFP cells (s),
KNRK-PAR2(dST363/6A)
cells (m), and hBRIE cells
(h). Cells were incubated
with 50 mM AP for 0–30 min
at 378C and endocytosis was
determined by measuring
surface Flag immunoreactiv-
ity by flow cytometry. *P ,
0.05 compared with cells ex-
pressing PAR2 alone or
PAR2 plus ARR-GFP cells,
n 5 3. (b–d) Localization of
PAR2 and b-arrestin by im-
munofluorescence and con-
focal microscopy. KNRK-
PAR21ARR-GFP cells (b),
KNRK-PAR2(dST363/6A)1
ARR-GFP cells (c), or
KNRK-PAR2(dST363/6A)
(d) were incubated with 50
nM trypsin for 0–30 min at
378C. PAR2 was localized by
immunofluorescence and
b-arrestin was detected using
GFP (b and c) or by immuno-
fluorescence (d). The same
cells are shown in each row
and the images in the right
panel are formed by super-
imposition of the images
from the other two panels in
the same row. Representa-
tive of two experiments. In
KNRK-PAR21ARR-GFP
cells, note redistribution of
b-arrestin to the plasma
membrane at 5 min (arrowheads) and to endosomes at 30 min (arrows), where it colocalizes with PAR2. In KNRK-PAR2(dST363/
6A)1ARR-GFP cells and in KNRK-PAR2(dST363/6A), note that PAR2 remains at the plasma membrane (arrowheads) and b-arres-
tin remains in the cytosol (arrows) with no colocalization. Bar, 10 mm.DeFea et al. b-Arrestin and ERK Localization 1273
present at the plasma membrane, ARR-GFP was diffusely
localized in the cytosol and was sometimes detected at the
plasma membrane, whereas immunoreactive endogenous
b-arrestin was mostly detected in the cytosol (Fig. 3, c and
d). Trypsin did not induce endocytosis of PAR2(dST363/
6A). ARR-GFP and endogenous b-arrestin were mostly
retained in the cytosol and did not colocalize with PAR2
(dST363/6A) at the plasma membrane or in endosomes.
These results indicate that PAR2(dST363/6A) does not in-
teract with b-arrestins at the plasma membrane, which
probably explains its resistance to desensitization and en-
docytosis. Furthermore, overexpression of ARR-GFP does
not compensate for the inability of the mutant receptor to
internalize.
We examined the ability of this internalization-resis-
tant and desensitization-defective mutant receptor to acti-
vate ERK1/2. In KNRK-PAR2(dST363/6A) cells, 50 nM
trypsin caused a 5.4 6 1-fold increase in ERK activity at 5
min, which is similar to that observed in KNRK-PAR2
cells (Fig. 4 a). However, the ERK response, like the Ca21
response, remained elevated in cells expressing PAR2
(dST363/6A). In KNRK-PAR2(dST363/6A) cells, trypsin
stimulated a 6.1-fold increase in ERK1/2 activation (Fig. 4
b,  m). Similar results were observed in HEK293 cells
transfected with PAR2(dST363/6A) (not shown). Neither
overexpression of ARR-GFP (Fig. 4 b, D) nor of
ARR319-418-GFP (Fig. 4 b, r) in KNRK-PAR2(dST363/
6A) cells altered ERK1/2 activation by the mutant recep-
tor. Thus, whereas b-arrestin–dependent internalization of
PAR2 is required for activation of ERK1/2 by the wild-
type receptor, it is not required for a mutant receptor that
is capable of prolonged signaling. These results suggest
that the mutant receptor activates ERK1/2 by an alterna-
tive pathway that circumvents the requirement for recep-
tor internalization.
Wild-type and Mutant PAR2 Activate ERK1/2 by 
Different Pathways
We compared the mechanism by which wild-type PAR2
and PAR2(dST363/6A) activate ERK1/2 to provide addi-
tional information about the importance of b-arrestins in
agonist-induced activation of ERK1/2. Agonists of GPCRs
can activate ERK1/2 by multiple pathways. For Gai-cou-
pled receptors, agonist-induced ERK activation is medi-
ated by G protein bg subunits and involves tyrosine phos-
phorylation of the same intermediates, such as shc and
Grb2, used by receptor tyrosine kinases to activate ras and
phosphorylate the MEK1 kinase raf-1, an event which is
sensitive to pertussis toxin (Hawes et al., 1995; Luttrell et al.,
1995; van Biesen et al., 1995; Daaka et al., 1997; Della
Rocca et al., 1997, 1999). GPCRs can also transactivate re-
ceptor tyrosine kinases (Luttrell et al., 1997a). In addition,
both Ca21 mobilization and EGF receptor transactivation
can lead to PYK2 phosphorylation (Dikic et al., 1996; Lev
et al., 1995; Eguchi et al., 1999; Zwick et al., 1999), which
feeds into the ras-dependent pathway at the level of shc
phosphorylation. Thus, there are a number of potential
pathways by which PAR2 could activate ERK1/2.
Because activation of PAR2 leads to Ca21 mobilization
and stimulation of PKC, which can directly phosphorylate
raf-1 (Hawes et al., 1995; Schönwasser et al., 1998), we first
examined the role of PKC in PAR2-mediated activation of
ERK1/2. We examined the effect a nonselective PKC
inhibitor (GF109203X) and of a specific inhibitor of
the Ca21-dependent PKCb (LY379196) on trypsin-stimu-
lated ERK phosphorylation. In KNRK-PAR2 cells, both
GF109203X and LY379196 reduced trypsin-stimulated
ERK phosphorylation by 52 6 5% and 48 6 4%, re-
spectively (Fig. 5 a). Likewise, in hBRIE cells, both
GF109203X and LY379196 reduced trypsin-stimulated
ERK1/2 phosphorylation by 78 6 2% and 50 6 5%, re-
spectively (Fig. 5 a). In HEK293-PAR2 cells, GF109203X
reduced trypsin-stimulated ERK1/2 phosphorylation
by 70 6 10% (not shown). However, in KNRK-
PAR21ARR319-418-GFP and KNRK-PAR2(dST363/6A)
cells (Fig. 5 a), ERK1/2 activation was insensitive to both
PKC inhibitors. Therefore, trypsin-stimulated activation
of ERK1/2 by the wild-type receptor is predominantly me-
diated by PKC, some of which is through the specific
PKCb isozyme, whereas the mutant receptor activates
ERK1/2 by a PKC-independent mechanism. To exclude
the possibility that activation by PAR2 involves uncou-
pling from Gaq and coupling to a PTX-sensitive G pro-
tein, similar to b2-AR which uncouples from Gas and
couples to Gai (Daaka et al., 1997), we examined the sen-
sitivity of trypsin-stimulated ERK phosphorylation to
PTX. Pretreatment with PTX did not affect trypsin-stimu-
lated phosphorylation of ERK1/2 in KNRK-PAR2 cells
(Fig 5 a). If the internalization-defective PAR2(dST363/
6A) activates ERK1/2 by a PKC and PTX-independent
pathway, we hypothesized that it was doing so by a ras-
dependent pathway involving phosphorylation of some of
the same proteins used by receptor tyrosine kinases. To
Figure 4. (a) PAR2-mediated ERK1/2 activity.
KNRK-PAR2 (e) and KNRK-PAR2(dST363/
6A) (m) cells were treated with 50 nM trypsin for
0–30 min, and ERK activity was measured
using the MBP assay. (b) Activation of ERK1/2.
KNRK-PAR2(dST363/6A) (m), KNRK-PAR2
(dST363/6A)1ARR-GFP (n), and KNRK-PAR2
(dST363/6A)1ARR319-418-GFP (r) cells were
treated with 50 nM trypsin for 0–30 min and
phosphorylation was assessed using antibodies to
pERK1/2. *P , 0.05 compared with KNRK-
PAR2 cells, n 5 3.The Journal of Cell Biology, Volume 148, 2000 1274
test this possibility, we examined the effect of the nonspe-
cific tyrosine kinase inhibitor genistein, the epidermal
growth factor receptor (EGFR) inhibitor tyrphostin 25,
and the expression of dominant negative N17ras on
trypsin-stimulated activation. In KNRK-PAR2(dST363/
6A) cells, genistein abolished trypsin-stimulated activation
of ERKs and tyrphostin 25–inhibited activation by 55 6
5% (Fig. 5 a). In KNRK-PAR2 and hBRIE cells, both
genistein and tyrphostin 25 inhibited trypsin activation of
ERK1/2 by ,20%. These results suggest that activation by
the mutant receptor occurs via activation of tyrosine ki-
nase pathways, in part, because of transactivation of
EGFR, whereas the wild-type receptor activation of
ERK1/2 is predominantly independent of tyrosine kinase
activation. Expression of N17ras with PAR2(dST363/6A)
but not wild-type PAR2 also abolished trypsin-stimulated
activity, whereas ERK1/2 activation by 10% serum was
abolished in both cell lines (Fig. 5 a). These results
strongly suggest that the mutant receptor might utilize a
ras-dependent pathway, whereas the wild-type receptor
might not. However, it is somewhat difficult to interpret
the effects of a dominant negative ras in a ras-transformed
cell line. Unfortunately, attempts to express N17ras in ei-
ther hBRIE or HEK293 cells have been unsuccessful.
Therefore, to further clarify the difference between the
mechanisms of ERK1/2 activation used by these two re-
ceptors, we examined other known components of the ras-
dependent pathway.
First, we examined tyrosine phosphorylation of PYK2
and the adaptor protein Shc. PYK2 is a member of the fo-
cal adhesion kinase family that has been shown to bind src,
phosphorylate Shc, and activate ERK1/2 in response to ex-
tracellular signals that mobilize intracellular Ca21, activate
PKC, or transactivate EGFR (Dikic et al., 1996; Eguchi et al.,
1999; Zwick et al., 1999). In KNRK-PAR2 cells, trypsin in-
duced only a mild phosphorylation of PYK2 and shc (1.3 6
0.1- and 1.2 6 0.2-fold, respectively), compared with the
more robust phosphorylation (3.7 6 0.3- and 2.5 6 0.2-
fold, respectively) in KNRK-PAR2(d363/6A) cells (Fig. 5,
b and c). This increase in PYK2 phosphorylation was simi-
lar to that observed for another Gaq-coupled receptor, the
neurokinin-1 receptor (NK1R), activation of which results
in nuclear ERK1/2 activity and proliferation (DeFea,
K.A., and N.W. Bunnett, unpublished observations). In
hBRIE cells, no significant trypsin-stimulated PYK2 phos-
phorylation (not shown) or shc phosphorylation was ob-
served, although 10% of serum did stimulate shc phosphor-
ylation (Fig. 5 d). Furthermore, upon trypsin treatment,
tyrosine-phosphorylated PYK2 associated with src in
KNRK-PAR2(dST363/6A) cells, whereas no significant
increase in tyrosine-phosphorylated PYK2 association oc-
curred in KNRK-PAR2 cells (Fig. 5 e), although a signifi-
cant amount of unphosphorylated PYK2 was associated
with src in unstimulated KNRK-PAR2 and KNRK-
PAR2(dST363/6A) cells (Fig. 5 f).
Thus, b-arrestin–mediated receptor internalization is re-
quired for PAR2 activation of ERK1/2 only if the receptor
is able to desensitize normally. If the signal generated by
the receptor is prolonged because of point mutations, an
alternate pathway is used. Wild-type PAR2 activates
ERK1/2 principally by a b-arrestin– and PKC-dependent
mechanism, whereas PAR2(dST363/6A) appears to cou-
ple to ERK1/2 by a tyrosine kinase– and ras-dependent
mechanism. The mutant PAR2 pathway might also in-
volve transactivation of EGFR, phosphorylation of PYK2
and shc, and activation of src.
PAR2 Association with b-Arrestins Determines the 
Localization and Specificity of ERK1/2
Our results raise the question of why the b-arrestin–depen-
dent pathway for ERK1/2 activation exists. To address this
question, we examined the next step in ERK1/2 activation,
translocation of the activated kinases to the nucleus, to de-
termine if the pathway of ERK1/2 activation affects the
subcellular localization of the activated kinases.
To investigate whether activated ERK1/2 translocates
to the nucleus, we incubated KNRK-PAR2 or KNRK-
PAR2(dST363/6A) cells with 50 nM trypsin, 50 mM AP or
10% serum, and analyzed cytosolic and nuclear fractions
for pERK immunoreactivity. In the cytosol, trypsin in-
duced a 6 6 2-fold increase in ERK1/2 phosphorylation in
KNRK-PAR2 cells (Fig. 6 a, d) and a 7 6 1-fold increase
in KNRK-PAR2(dST363/6A) cells (Fig. 6 a, m) that was
maintained for 5–30 min. In the nucleus, trypsin stimu-
Figure 5. Mechanism of PAR2-mediated activation of ERK1/2.
(a) KNRK-PAR2, hBRIE, KNRK-PAR21ARR319-418, and
KNRK-PAR2(dST363/6A) cells were untreated (control, con),
or incubated with 100 nM GF109203X (GFX), 20 nM LY379196
(LY), 100 ng/ml PTX, 10 mM genistein (GEN), 20 mM tyrphostin
25 (TP), or were cotransfected with N17ras. Cells were incubated
with 50 nM trypsin for 5 min. *P , 0.05 compared with untreated
cells, n 5 4. (b–f) Analysis of KNRK-PAR2 and KNRK-
PAR2(dST363/6A) cells by immunoprecipitation (IP) and West-
ern blotting (WB). Cells were incubated with 50 nM trypsin for 5
min. Extracts were immunoprecipitated with antibodies to PYK2
(b), Shc (c and d), and src (e–g). Blots were probed for phospho-
tyrosine (b–e), PYK2 (f), and src (g).DeFea et al. b-Arrestin and ERK Localization 1275
lated a large and rapid increase in ERK1/2 phosphoryla-
tion (14 6 2-fold at 5 min) in KNRK-PAR2(dST363/6A)
cells (Fig. 6 b, m). In marked contrast, trypsin stimulated
only a minor increase in nuclear ERK1/2 phosphorylation
in KNRK-PAR2 cells (Fig. 6 b, d). The minor increase in
ERK1/2 activation observed in PAR21ARR319-418-GFP
cells appears in both nuclear and cytosolic fractions (Fig.
6, a and b, s). However, the nuclear ERK1/2 activity
observed in these cells was not significantly higher than
that observed in KNRK-PAR2 cells. Similar results were
obtained using AP (not shown). Addition of 10% serum
stimulated a 10 6 1.0-fold and a 14.6 6 2-fold increase
in cytosolic and nuclear ERK1/2 activation in both cell
lines, respectively (not shown), which is similar to the nu-
clear activity observed with the mutant receptor. To en-
sure that cytosolic retention of ERK1/2 was not a result of
exogenous PAR2 expression, we examined the subcellu-
lar localization of activated ERK1/2 in hBRIE cells.
While treatment of hBRIE cells with 50 nM trypsin re-
sulted in a 5.0 6 1.0-fold increase in cytosolic ERK1/2 ac-
tivity (Fig. 6 c, h), no marked increase in nuclear ERK1/2
activity was observed (Fig. 6 d, h). In contrast, 10% se-
rum stimulated a 7.5 6 1.5-fold increase in cytosolic and a
6.8 6 0.8-fold increase in nuclear ERK1/2 activation (Fig.
6, c and d, r).
To confirm these findings, that the mutant and wild-type
PAR2 differ in their ability to stimulate nuclear transloca-
tion of activated ERKs, we examined trypsin-induced
translocation of ERK2 tagged with GFP. We transiently
expressed ERK2-GFP in KNRK-PAR2 or KNRK-
PAR2(dST363/6A) cells, incubated cells with 50 nM tryp-
sin, and observed cells by confocal microscopy. In KNRK-
PAR2 cells, trypsin did not affect the distribution of
ERK2-GFP, which remained in the cytosol at all time
points (Fig. 6 e, left). In contrast, trypsin stimulated accu-
mulation of ERK2-GFP in the nucleus of KNRK-PAR2
(dST363/6A) cells within 5 min, and it remained there for
30 min (Fig. 6 e, right). Thus, trypsin-stimulated ERK1/2
Figure 6. Nuclear trans-
location of ERK1/2. (a–d)
Subcellular fractionation of
activated ERK1/2. KNRK-
PAR21ARR-GFP cells
(d), KNRK-PAR21
ARR319-418-GFP cells (s), or
PAR2(dST363/6A) cells (s)
were incubated with 50 nM
trypsin for 0–30 min at 378C,
and pERK was determined in
the cytosolic (a) and nuclear
(b) fractions (n 5 3). hBRIE
cells were incubated with 50
nM trypsin (h) or 10% se-
rum (r), and pERK was de-
termined in the cytosolic (c)
and nuclear (d) fractions. (e)
KNRK-PAR2 and KNRK-
PAR2(dST363/6A) cells,
transiently transfected with
ERK2-GFP, were incubated
with 50 nM trypsin at 378C,
and translocation of ERK2-
GFP was observed by confo-
cal imaging. Representative
of eight experiments. In
KNRK-PAR2 cells, note that
ERK2-GFP remains cyto-
solic but, in KNRK-
PAR2(dST363/6A) cells, it
redistributes to the nucleus.
(f and g) Proliferative re-
sponses to AP and serum.
KNRK-PAR2 (f, h) and
KNRK-PAR2(dST363/6A)
cells (f, j) or hBRIE cells (g)
were incubated with 50 mM
AP or 20% FCS for 24 h, and
incorporation of [3H]thymi-
dine and cell number were
measured. *P , 0.05 com-
pared with untreated cells or
KNRK-PAR2 cells, n 5 3.The Journal of Cell Biology, Volume 148, 2000 1276
activity through the b-arrestin–dependent pathway is pre-
dominantly cytosolic.
Activation of the internalization-deficient PAR2 results
in nuclear translocation of activated ERK1/2, an event
that is a requirement for mitogenesis induced by a number
of growth factors (Brunet et al., 1999). Therefore, we hy-
pothesized that PAR2 agonists would stimulate prolifera-
tion of cells expressing PAR2(dST363/6A), but not in cells
expressing wild-type PAR2 or in hBRIE cells. To assess
proliferation, we incubated cells with 50 mM AP for 24 h
and measured both [3H]thymidine incorporation into
DNA and cell number. In KNRK-PAR2 cells, AP had no
effect on [3H]thymidine incorporation or cell number (Fig.
6 f). In contrast, in KNRK-PAR2(dST363/6A) cells, AP
induced a 2.4 6 0.8-fold increase in [3H]thymidine incor-
poration and a 2.7 6 0.5-fold increase in cell number,
which is similar to that observed with serum. Similarly, in
hBRIE cells, whereas serum induced a 2.5 6 0.3-fold in-
crease in [3H]thymidine incorporation and cell number,
AP had no effect (Fig. 6 g).
Trypsin Induces the Formation of a Scaffolding 
Complex Containing PAR2, b-Arrestin, raf-1, and 
Activated ERK1/2
Disruption of the b-arrestin–dependent mechanism of
ERK1/2 activation by receptor mutation led to the use of
an alternative pathway that resulted in nuclear ERK1/2
activity and proliferation. Therefore, we hypothesized that
b-arrestin is necessary for the cytosolic retention of the ac-
tivated ERK1/2 through the formation of a scaffolding
complex. Because previous studies of the b2-AR demon-
strated agonist-induced association of b-arrestin and src
(Luttrell et al., 1999), we examined the possibility that
PAR2 agonists induce association of b-arrestin with com-
ponents of the MAPK cascade. We incubated cells with
50 nM trypsin and localized b-arrestins and raf-1 by con-
focal microscopy. In KNRK-PAR21ARR-GFP cells, tryp-
sin stimulated translocation of b-arrestin and raf-1 from
the cytosol to the plasma membrane, where they colo-
calized at 5 min (Fig. 7 a). Although trypsin also stimu-
lated membrane translocation of raf-1 in cells expressing
internalization-defective PAR2(dST363/6A)1ARR-GFP,
b-arrestin remained in the cytosol and did not colocalize
with raf-1 (Fig. 7 b). To confirm that colocalization of raf-1
and b-arrestin reflected protein–protein interaction, and
to ensure that this association was not due to over-
expression of ARR-GFP, KNRK-PAR2, and KNRK-
PAR2(dST363/6A), cells were treated with 50 nM trypsin
or 50 mM AP for 5 min, and the association of raf-1 with
b-arrestin was determined by coimmunoprecipitation.
While trypsin and AP stimulated a 5 6 0.5- (Fig. 7 b) and
Figure 7. Trypsin induced as-
sociation of b-arrestin and
raf-1. (a and b) Localization of
b-arrestin and raf-1 by im-
munofluorescence and con-
focal microscopy. KNRK-
PAR21ARR-GFP cells (a) or
KNRK-PAR2(dST363/6A)1
ARR-GFP cells (b) were in-
cubated with 50 nM trypsin for
0 or 5 min at 378C. b-Arrestin
was localized using GFP and
raf-1 was localized by immu-
nofluorescence. The same cells
are shown in each row and the
images in the right panel are
formed by superimposition of
images from the other two
panels in the same row. Rep-
resentative of two experiments.
In KNRK-PAR21ARR-GFP
cells, note the redistribution of
b-arrestin and raf-1 from the
cytosol at 0 min (arrows) to
the plasma membrane at 5 min
(arrowheads), where they
colocalize. In KNRK-PAR2
(dST363/6A)1ARR-GFP cells,
note that b-arrestins remain in
the cytosol (arrows) and raf-1
redistributes to the plasma membrane at 5 min (arrowheads). (c–f) Coimmunoprecipitation of raf-1 and b-arrestin. Cells were incu-
bated with 50 nM trypsin for 0–30 min at 378C, lysed, immunoprecipitated (IP) using antibodies to GFP or b-arrestin-1/2, and analyzed
by Western blotting (WB) with a raf-1 antibody. (c) In KNRK-PAR2 cells, but not in KNRK-PAR2(dST363/6A) cells, b-arrestin and
raf-1 coprecipitated. (d) Similarly, in KNRK-PAR21ARR-GFP cells but not KNRK-PAR2(dST363/6A)1ARR-GFP cells ARR-GFP
and raf-1 coprecipitated with antibodies to GFP. (e) In KNRK-PAR21ARR319-418-GFP cells, endogenous b-arrestin and raf-1 coprecip-
itated, but ARR319-418 and raf-1 did not coprecipitate. (f) In hBRIE1ARR-GFP cells, ARR-GFP and raf-1 coprecipitated. Bars, 10 mm.DeFea et al. b-Arrestin and ERK Localization 1277
4.8 6 0.8-fold increase (not shown), respectively, in associ-
ation with b-arrestin and raf-1 over basal in KNRK-PAR2
cells, this association was not observed in KNRK-PAR2
(dST363/6A) cells (Fig. 7 c). Similar results were obtained
in KNRK-PAR21ARR-GFP cells (Fig. 7 d) and expres-
sion of ARR-GFP with PAR2(dST363/6A) did not com-
pensate for the mutant receptor’s inability to stimulate
raf-1/b-arrestin association (Fig. 7 d). Expression of
ARR319-418-GFP did not inhibit the ability of endogenous
b-arrestin to bind raf-1, but the dominant negative b-arres-
tin did not associate with raf-1 (Fig. 7 e). In hBRIE1
ARR-GFP cells, trypsin induced a 2.8 6 0.3-fold increase
in raf-1 association with ARR-GFP after 5 min, and the as-
sociation was maintained for 30 min (Fig. 7 f). Together,
these data suggest that PAR2-mediated activation of
ERK1/2 involves the formation of a signaling complex,
which might serve to retain the activated ERK1/2 in the
cytosol. To investigate this possibility, we incubated cells
with 50 nM trypsin or 50 mM AP for 5 min, and fraction-
ated lysates by gel filtration chromatography. Fractions
within the included volume were analyzed by SDS-PAGE,
and Western blots were probed for PAR2, b-arrestin, raf-1,
pERK1/2, and total ERK1/2. For each of these proteins,
the band density in every fraction is expressed as a per-
centage of the total protein detected in all fractions (see
Materials and Methods) and complex formation is de-
picted in the graphs (Fig. 8). (Note that total ERK is rep-
resented as the sum of p-ERK and unphosphorylated
ERK.) Representative Western blots of the fractions con-
taining the complex are shown as insets. Since the expres-
sion of ARR-GFP does not increase ERK1/2 activation or
raf-1/b-arrestin association, cells overexpressing ARR-
GFP were not used in the gel filtration experiments.
In KNRK-PAR2 and hBRIE cells, PAR2 agonists
caused a marked redistribution in the elution profiles that
resulted in the coelution of pERK, raf-1, b-arrestin, and
Figure 8. Gel filtration analysis of an ERK signaling complex. KNRK-PAR2 (a and b), KNRK-PAR2(dST363/6A) cells (c and d), or
hBRIE cells (e and f), or KNRK-PAR21ARR319-418-GFP cells (g) were untreated (a, c, and e) or incubated with 50 mM AP (b, d, f, and
g) for 5 min. Cell lysates were fractionated on a S300 Sephacryl column. The presence of pERK, raf-1, b-arrestin-1, and PAR2 in each
fraction was determined by Western blotting (inset). PAR2 was detected using HA.11 antibody in KNRK cells and 2N antibody in
hBRIE cells. Results are expressed as a percentage of the total protein for each partition coefficient (s) (n 5 3). The bracketed columns
represent regions where proteins coeluted. Representative Western blots are shown of fractions containing the complex in KNRK-
PAR2 cells (w, s 5 0.34), hBRIE cells (q, s 5 0.31–34), and in KNRK-PAR21ARR319-418-GFP (*, s 5 0.45). (h) The Stoke’s radii of
the four molecular mass standards and the complex in KNRK-PAR2 cells (w,  z6.2), hBRIE cells (q,  z6.2–6.6), and KNRK-
PAR21ARR319-418-GFP (*, z5 nm) are graphed as a function of the error function complement of s.The Journal of Cell Biology, Volume 148, 2000 1278
PAR2 in the same fractions, with partition coefficients (s)
of 0.34 for KNRK-PAR2 cells and 0.31–0.34 for hBRIE
cells (Fig. 8, b and f, w and q, respectively). In untreated
cells (Fig. 8, a, c, and e) and in trypsin- or AP-stimulated
KNRK-PAR2(dST363/6A) cells (Fig. 8 d), coelution of all
four proteins was not observed. Notably, in trypsin- or
AP-treated KNRK-PAR2 and hBRIE cells, .80% of the
pERK coeluted with raf-1, b-arrestin, and PAR2. In con-
trast, in trypsin- or AP-treated KNRK-PAR2(dST363/6A)
cells, ,2% of the pERK eluted in these fractions. The ap-
proximate Stoke’s radius of the putative complexes ob-
served in stimulated KNRK-PAR2 and hBRIE cells was
calculated from the error function complement of s and is
between 6 and 7 nm, which corresponds to a molecular
mass of z250–300 kD (Fig. 8 h). Interestingly, in trypsin-
stimulated KNRK-PAR21ARR319-418-GFP cells, all four
proteins coeluted at a partition coefficient of 0.45, al-
though the ERK1/2 in the complex was not phosphory-
lated and the apparent Stoke’s radius of the complex was
only 5 nm. PAR2 activation resulted in coelution of
PAR2, b-arrestin, raf-1, and pERK1/2 in KNRK-PAR2
and hBRIE cells. To determine if these proteins were as-
sociated in a complex, we used immunoprecipitation and
Western blotting. Immunoprecipitation of gel filtration
fractions from KNRK-PAR2 cells, containing the puta-
tive complex with antibodies to pERK1/2, coprecipitated
PAR2, b-arrestin 1, and raf-1 (Fig. 9 a). Similarly, immu-
noprecipitation with antibodies to b-arrestin 1/2 coprecipi-
tated pERK (Fig. 9 a). In hBRIE cells, antibodies to b-arres-
tin 1/2 coprecipitated pERK and raf-1 (Fig. 9 b). In both
cell lines, anti-IgG did not precipitate PAR2, b-arrestin,
raf-1, or pERK. Coprecipitation of PAR2 in hBRIE cells
was hindered by the lack of PAR2 antibody sensitive
enough to detect the low levels of protein that were puri-
fied in this complex. However, it is noteworthy that PAR2
coeluted in the same fractions as b-arrestin, raf-1, and
pERK only upon trypsin or AP treatment, and that the
size range of this putative complex is similar to that puri-
fied from transfected cells. From these data, we conclude
that agonists of PAR2 induce the formation of a scaffold-
ing complex near the inner leaflet of the plasma mem-
brane, comprising internalized receptor, b-arrestin, raf-1,
activated ERK, and possibly other members of the MAPK
cascade.
In KNRK-PAR2(dST363/6A) cells and untreated hBRIE
cells, a portion of b-arrestin and phospho-ERK coeluted
at partition coefficients 0.49–0.67. However, these proteins
could not be coprecipitated (not shown) and probably do
not associate. b-Arrestin might exist as a tetramer (Hirsch
et al., 1999; Schubert et al., 1999), which could account for
its faster migration than would be predicted for a protein
of its size, although the significance of b-arrestin multi-
mers is unclear. The coelution of small amounts of pERK,
raf-1, and b-arrestin at partition coefficients .0.6 in un-
treated hBRIE cells (Fig. 8 e) cannot reflect a complex as
the Stoke’s radius of molecular mass standards in these
fractions is ,2.5 nm, the size of purified ERK alone
(Khokhlatchev et al., 1998). The fact that endogenous
b-arrestin can still associate with raf-1, and that these two
proteins still coelute with unphosphorylated ERK1/2 and
PAR2 even in the presence of ARR319-418, suggests that at
least part of the complex, that comprising PAR2, b-arres-
tin, raf-1 and ERK1/2, assembles before interaction with
the clathrin-coated pit. It will be of interest in the future to
examine the effects of dominant negative mutants of pro-
teins involved in later steps of endocytosis on ERK1/2 ac-
tivation and complex assembly, and to identify other puta-
tive components of this complex.
Discussion
Although several studies have suggested a requirement
for b-arrestin–mediated receptor endocytosis for agonist-
induced ERK1/2 activity, the reason for this requirement
has not been elucidated. Our results suggest that the Gaq-
coupled receptor, PAR2, activates ERK1/2 through a
PKC-dependent, PTX-insensitive pathway, by a mecha-
nism that requires receptor association into a multiprotein
complex comprising internalized receptor, b-arrestin, raf-1,
activated ERK1/2, and perhaps other components of the
MAPK pathway. Importantly, this complex forms in trans-
fected cell lines and also in enterocytes that naturally ex-
press PAR2 and which are regulated under physiological
circumstances by trypsin in the intestinal lumen (Kong et al.,
1997). This complex might ensure that ERK1/2 activity re-
mains in the cytosol and does not translocate to the nu-
cleus to stimulate proliferation, and the data shown here
support that hypothesis.
These findings suggest a novel role for scaffolding com-
plexes in determining MAPK localization and the conse-
quences of its activation (Fig. 10). A role for scaffolding
complexes in the activation of ERK1/2 is an evolutionarily
conserved one from yeast to mammalian cells (Luttrell et
al., 1997b; Madhani et al., 1997). These scaffolding com-
plexes bring components of the MAPK cascade in proximity
to each other and, thereby, maintain substrate specificity.
The PAR2/b-arrestin/raf-1/pERK complex may also serve
to maintain substrate specificity, by preventing translocation
of activated ERK1/2 to the nucleus, allowing phosphoryla-
tion only of cytosolic substrates. Comparisons between wild-
type PAR2 and a mutant receptor, which does not interact
with b-arrestins and thus fails to desensitize and internalize,
Figure 9. Coprecipitation of components of the b-arrestin–con-
taining signaling complex. (a) Fractions from the gel filtration
columns of AP-stimulated KNRK-PAR2 cells at partition coeffi-
cients 0.31–0.34 were pooled, concentrated, and immunoprecipi-
tated with pERK or b-arrestin-1/2 antibodies. Western blots
were probed for PAR2 using the HA.11 antibody, b-arrestin-1,
raf-1, and pERK. (b) Fractions from the gel filtration columns of
AP-stimulated hBRIE cells at partition coefficients 0.31–0.34
were similarly processed, immunoprecipitated with a b-arrestin-
1/2 antibody, and blotted with antibodies to pERK and raf-1.DeFea et al. b-Arrestin and ERK Localization 1279
provided important insights into the function of b-arres-
tin–dependent receptor trafficking. The mechanism by
which an internalization and desensitization-defective mu-
tant PAR2 activates ERK1/2 appears to involve activation
of tyrosine kinases, possibly through the phosphorylation
of PYK2, followed by its association with src and subse-
quent phosphorylation of the adaptor protein, Shc. The
precise mechanism of ERK1/2 activation, however, has
not been elucidated. Although both wild-type PAR2 and
PAR2(dST363/6A) mobilize intracellular Ca21, the pro-
longed signal exerted by the mutant receptor and its abil-
ity to transactivate the EGFR may account for its ability to
activate PYK2, whereas the wild-type receptor does so
only weakly (Fig. 10). The important point is that the mi-
togenic pathway available to the mutant receptor is un-
available to the wild-type receptor because ERK1/2 acti-
vation by PAR2 is tightly linked to b-arrestin–mediated
desensitization and endocytosis. By preventing activated
ERK1/2 from translocating to the nucleus, this mechanism
may permit more precise control over a potentially mito-
genic pathway.
The mechanisms by which b-arrestin–containing com-
plexes activate ERK1/2 and prevent their translocation to
the nucleus remain to be determined. Peak ERK1/2 activ-
ity is observed after 5 min of trypsin stimulation, at which
point only one third of the surface receptor is internalized,
suggesting that either the only a portion of the PAR2,
much of which is in the initial pool of internalized recep-
tor, mediates the ERK1/2 response. The fact that domi-
nant negative b-arrestin inhibits receptor association with
clathrin-coated pits and ERK1/2 activation, but not associ-
ation of ERK1/2 with b-arrestin–bound PAR2 and raf,
suggests that early endosome formation might be required
for activation of ERK1/2. Studies of purified ERK1/2 sug-
gest that dimerization is a prerequisite for nuclear translo-
cation (Khokhlatchev et al., 1998). Recent reports suggest
that the association of MEK1 also serves to anchor un-
stimulated ERK1/2 in the cytoplasm of unstimulated cells
(Fukuda et al., 1997) and that activated MEK is itself regu-
lated by dynamin-mediated endocytosis (Kranenburg et
al., 1999). In addition, a novel member of the importin fam-
ily of nuclear transporters is required for nuclear transloca-
tion of p38, another member of the MAPK family (Ferrigno
et al., 1998). Thus, the b-arrestin complex may sequester ac-
tivated ERK1/2 to preclude their dimerization, prolong their
association with MEK1, or impede their interaction with
transport proteins, all of which could prevent nuclear trans-
location. In contrast, activation of the mutant PAR2 induced
a shift in the apparent Stoke’s radius of pERK (Fig. 8, b and
c), which would be consistent with the formation of ERK
dimers, and with the ability of the mutant receptor to induce
nuclear translocation of ERK1/2.
The b-arrestin–containing signaling complex is larger than
might be predicted if only PAR2, b-arrestin, raf-1, and
pERK were present at equal stoichiometries and, thus, the
precise composition of the complex is presently unknown.
We do not know whether pERK1/2 exists in the complex as
monomers or dimers. Furthermore, the complex may contain
other components of the MAPK pathway, such as MEK1, or
other signaling proteins, such as PKC. Preliminary results
suggest that MEK1 also coelutes from gel filtration columns
with the complex described here, but it has been technically
difficult to copurify as MEK1 with b-arrestin, perhaps be-
cause MEK1 dissociates from the complex during the ex-
periment (DeFea, K.A., and N.W. Bunnett, unpublished
observation). The association of the complex components
identified here is quite stable, as it survives detergent solu-
bilization, dilution, gel filtration, reconcentration, and im-
munoprecipitation; other complex components may be
lost during these manipulations.
Nuclear translocation of ERK1/2 is an essential event in
the control of gene activation and the cell growth and dif-
ferentiation induced by some mitogens, and enforced cyto-
plasmic retention of activated ERK1/2 has been shown to
inhibit growth factor–induced proliferation, while having
no effect on phosphorylation of cytoplasmic substrates
(Brunet et al., 1999). The cytoplasmic targets of PAR2-
induced ERK1/2 remain to be determined. However, PAR2
agonists activate phospholipase A2 to generate arachidonic
acid, and also stimulate cyclooxygenase-2 expression in
an ERK-dependent manner in enterocytes (Kong, W.,
and N.W. Bunnett, unpublished observations). Cytosolic
ERK1/2 may also phosphorylate cytoskeletal proteins, sug-
gesting a role in cell migration and morphogenesis. In sup-
port of this possibility, preliminary studies in enterocytes
suggest that PAR2 agonists stimulate formation of F-actin
stress fibers in an ERK-dependent fashion (DeFea, K.A.,
and N.W. Bunnett, unpublished observations). Another
potential target of cytosolic ERK is b-arrestin itself. Re-
cent studies have shown that ERK phosphorylates b-arres-
tin, thereby impeding its ability to mediate endocytosis
and MAPK signaling of the b2-AR (Lin et al., 1999). Thus,
agonist-induced formation of this complex could bring
ERK1/2 in proximity to b-arrestin, which would provide
Figure 10. Model for b-arrestin–dependent and –independent
activation of ERK1/2 by PAR2. (1a) Trypsin cleavage and acti-
vation of wild-type PAR2 leads to transient Ca21 mobilization
and activation of PKC. (1b) PKC phosphorylates and activates
raf-1. (1c) PAR2 binds b-arrestin and desensitizes. (1d) Raf-1
and ERK1/2 associate with b-arrestin–bound receptor and (1e)
the complex associates with the clathrin-coated pit and ERK be-
comes activated. (1f) Cytosolic, active ERK1/2 phosphorylate
cytoskeletal proteins, microtubule-associated proteins (MAPs),
and phospholipase A2 (PLA2). (2a) Trypsin cleavage and activa-
tion of PAR2(dST363/6A) leads to sustained Ca21 mobilization
and transactivation of EGFR. (2b) Tyrosine phosphorylation of
kinases such as PYK2 occur, activating the classic ras-dependent
ERK1/2 pathway. (2c) ERK1/2 translocate to the nucleus. (2d)
ERK1/2 phosphorylate and activate nuclear proteins, leading to
DNA replication and cell growth.The Journal of Cell Biology, Volume 148, 2000 1280
negative feedback control of receptor endocytosis. It re-
mains to be determined whether association with b-arres-
tin also serves to cause cytoplasmic retention of ERK1/2,
which are activated by agonists of other GPCRs. Further-
more, naturally occurring variants of GPCRs have been
identified that exhibit diminished agonist-induced desensi-
tization (Li et al., 1997) and internalization (Böhm et al.,
1997), probably because of the inability to interact with
b-arrestins. It will be of great interest to determine the mi-
togenic potential of these receptors and to investigate
whether such variants of PAR2 also exist.
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